Daniel Lee Severance

Title: Daniel Lee Severance: Inventor in Biotechnology and Drug Discovery.

Introduction

Daniel Lee Severance is an inventor based in South San Francisco, California. His patent work includes compounds and therapeutic approaches aimed at inhibiting DNA polymerase theta, a potential target in cancer treatment. He is associated with 2 patents.

Latest Patents

One of Severance’s latest patents, “Substituted Thiadiazolyl Derivatives as DNA Polymerase Theta Inhibitors,” describes thiadiazolyl derivatives that inhibit DNA polymerase theta (Polθ). The disclosed compounds are designed to inhibit Polθ activity, particularly the ATP-dependent helicase activity of the enzyme. The patent also describes pharmaceutical compositions containing these compounds and methods for treating or preventing diseases that may respond to Polθ inhibition, including cancer and homologous recombination-deficient cancers.

Another listed patent is “Chemical Compounds and Uses Thereof,” reflecting a broader focus on chemical compounds and their potential applications.

Career Highlights

Severance’s listed company affiliations include IDEAYA Biosciences, Inc. and GlaxoSmithKline Intellectual Property (No. 4) Limited. These affiliations connect his patent activity with biotechnology and pharmaceutical research.

Collaborations

Among Severance’s listed coworkers are Melissa Fleury and James P. Phelan. Their shared professional context reflects the collaborative nature of research and intellectual property development in the life sciences.

Conclusion

Daniel Lee Severance’s patent portfolio centers on chemical compounds and potential cancer therapies, particularly approaches targeting DNA polymerase theta. His work and company affiliations place him within the biotechnology and pharmaceutical innovation landscape.